PBSGL Disease Modifying Drugs Module update
PBSGL Disease Modifying Drugs Module update`22/06/2018
We thought that you would like to know that following feedback from our groups we have made some changes and corrections to the PBSGL Disease Modifying Drugs Module.
The monitoring advice on mesalazine was incorrect – it is recommended, and advice on use in renal problems given. Minor changes made to table on 1 on DMARDs to reflect complexity of advice, and advice on paternal exposure to methotrexate changed in light of BNF current advice (effective contraception required).